GGrantIndex
← Search

Experimental Irradiators

$2,069P30FY2018CANIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications, trials & patents

Trial NCT02989636Trial NCT02516670Trial NCT02491411Trial NCT02489357Trial NCT02029950Trial NCT01935947Trial NCT01870596Trial NCT01783171Trial NCT01757639Trial NCT01578109Trial NCT01349972Trial NCT01349959Trial NCT01330173Trial NCT01264432Trial NCT01207726Trial NCT01207687Trial NCT01139970Trial NCT01132573Trial NCT01061749Trial NCT00971737Trial NCT00963807Trial NCT00899951Trial NCT00899548Trial NCT00898482Trial NCT00897338Trial NCT00897273Trial NCT00847171Trial NCT00795002Trial NCT00727441Trial NCT00673569Trial NCT00670917Trial NCT00660348Trial NCT00641303Trial NCT00641147Trial NCT00631137Trial NCT00616967Trial NCT00602771Trial NCT00588991Trial NCT00566098Trial NCT00524017Trial NCT00499733Trial NCT00499486Trial NCT00493025Trial NCT00492921Trial NCT00489281Trial NCT00478062Trial NCT00478010Trial NCT00471653Trial NCT00470093Trial NCT00469820Trial NCT00445484Trial NCT00433472Trial NCT00425477Trial NCT00407966Trial NCT00401024Trial NCT00389610Trial NCT00387465Trial NCT00381550Trial NCT00373191Trial NCT00369681Trial NCT00368914Trial NCT00363649Trial NCT00361296Trial NCT00356928Trial NCT00354640Trial NCT00343447Trial NCT00336063Trial NCT00334542Trial NCT00324870Trial NCT00313560Trial NCT00311623Trial NCT00305760Trial NCT00303927Trial NCT00293410Trial NCT00293397Trial NCT00293280Trial NCT00290732Trial NCT00287989Trial NCT00287872Trial NCT00281970Trial NCT00281866Trial NCT00278200Trial NCT00278161Trial NCT00278109Trial NCT00276744Trial NCT00276601Trial NCT00276588Trial NCT00274768Trial NCT00265915Trial NCT00265837Trial NCT00262834Trial NCT00258206Trial NCT00258180Trial NCT00255775Trial NCT00255710Trial NCT00245115Trial NCT00244959Trial NCT00242996Trial NCT00238368Trial NCT00238277

Abstract

ABSTRACT The Oncology Tissue Services (OTS) Core provides a number of technologies, services and scientific consultation to support the research of the Sidney Kimmel Comprehensive Cancer Center (SKCCC) members and other Johns Hopkins University (JHU) investigators. The Core was formerly known as the Tissue Microarray Core (TMA), when it provided TMA-related services, digital slide scanning and analysis, and routine histology services. With the addition of immunohistochemistry (IHC), immunofluorescence (IF) in situ hybridization (ISH) and the incorporation of the cytogenetics Core, the Core was renamed. It now provides traditional G-band metaphase analysis and FISH technologies, services added to this Core from a previous SKCCC CCSG Core. These expanded services enhance the ability of SKCCC researchers to perform tissue- based biomarker studies. The OTS Core has constructed greater than 826 TMAs for 55 investigators, containing tumor and normal tissue from most major organs. It has provided more than 80 new antibody workups and cored more than 2,500 blocks for RNA/DNA studies. It continues to provide essential cytogenetics services. Users published more than 104 manuscripts involving this resource since the last funding period began. In recent years, there has been tremendous growth in the service of providing tissue cores from FFPE tissue blocks for RNA and DNA molecular analyses. Instrumentation and expertise are available to automatically capture high-resolution digital images of both standard histology/IHC-based slides and TMA slides. The OTS Core obtained an automated slide stainer to convert laboratory discoveries of novel protein staining into clincal biomarkers. The Core provides Web-based software tools and two back-end databases (TMAJ/Spectrum) to facilitate all facets of research involving TMAs, routine slides and quantitative image analysis. The specific aims of this Core are: Aim 1: Provide affordable, high-quality histology, immunohistochemistry, cytogenetics, nucleic acid harvesting from tissues, digital slide scanning and analysis, and tissue microarray construction services. Aim 2: Identify and develop new technologies to support and speed translational research in cancer, including automated in situ hybridization and clinical translation of research immunohistochemistry discoveries. Aim 3: Support the Research Programs and respond to the needs of its users to by working with specific investigators on new protocols, procedures and custom procedures to meet their evolving histology, immunohistochemistry and slide scanning requirements. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

View original record on NIH RePORTER →